title: The maturation of myeloma cells correlates with sensitivity to chemotherapeutic agents.
abstract: We analyzed both morphologic and phenotypic findings of myeloma cells before and after chemotherapy in 21 patients with multiple myeloma. The morphologic analysis was based on the Greipp classification, and phenotypic analysis was performed by 3-color flow cytometry using the CD38 plasma gating method (Marrow plasma 38). Results with flow cytometry using a combination of MPC1, CD49e, and CD45 supported the morphologic findings for the myeloma cells. Treatment with 3 or 4 cycles of VAD (vincristine, doxorubicin, and dexamethasone) therapy was effective in reducing the total numbers of myeloma cells, but the proportion of immature myeloma cells increased after this treatment. However, the immature myeloma cells were reduced by high-dose melphalan (HD-Mel) therapy followed by autologous stem cell transplantation (ASCT). High-dose cyclophosphamide treatment for stem cell harvesting did not show an effect on the residual immature myeloma cells after VAD treatment. In addition, thalidomide was not effective in reducing the numbers of immature myeloma cells. These results suggest that VAD (3 or 4 cycles) therapy plus HD-Mel followed by ASCT is a reasonable treatment for multiple myeloma and that Marrow plasma 38 analysis is a useful method for monitoring the response of multiple myeloma to chemotherapy.
authors.affiliation: Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima734-8553, Japan.
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Kuroda
authors.forename: Akira
authors.initials: A
authors.lastname: Sakai
authors.forename: Yoshiko
authors.initials: Y
authors.lastname: Okikawa
authors.forename: Shoso
authors.initials: S
authors.lastname: Munemasa
authors.forename: Yuta
authors.initials: Y
authors.lastname: Katayama
authors.forename: Hideo
authors.initials: H
authors.lastname: Hyodo
authors.forename: Jun
authors.initials: J
authors.lastname: Imagawa
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Takimoto
authors.forename: Hajime
authors.initials: H
authors.lastname: Okita
authors.forename: Megu
authors.initials: M
authors.lastname: Ohtaki
authors.forename: Akiro
authors.initials: A
authors.lastname: Kimura
mesh_terms: D036541:ADP-ribosyl Cyclase / Q000032:analysis; D051997:ADP-ribosyl Cyclase 1; D000368:Aged; D015703:Antigens, CD / Q000032:analysis; D000970:Antineoplastic Agents / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D002454:Cell Differentiation; D003520:Cyclophosphamide / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008562:Membrane Glycoproteins; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology*; D010641:Phenotype; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D033581:Stem Cell Transplantation; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D015703:Antigens, CD; D000970:Antineoplastic Agents; D008562:Membrane Glycoproteins; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D036541:ADP-ribosyl Cyclase; C498154:CD38 protein, human; D051997:ADP-ribosyl Cyclase 1; D008558:Melphalan; D011241:Prednisone